Uterine leiomyomas are monoclonal benign tumors affecting a major proportion of the reproductively active female population. Despite its high occurrence rate, the understanding of the etiology and the molecular mechanism involving disease progression still remains poorly understood. Proteomics allows the identification of thousands of proteins inside the cell and simultaneous observation of any alteration in the protein expression which has, if any, impact on its clinical manifestation. As we know that proteins are the real time players of the cell hence, proteomics can provide a better understanding of the physiology of disease. Use of proteomics in uterine leiomyomas research might help to identify myoma specific proteins, disease pathway and importantly the potential biomarkers for early detection.
